Regulus Therapeutics INC Form 4 insider transactions
Preston Klassen, President & Head of R&D at Regulus Therapeutics, sold 31,445 shares of common stock on January 13, 2025, to cover tax withholding obligations related to vesting Restricted Stock Units (RSUs).
Regulus Therapeutics CEO, Joseph P. Hagan, acquired a total of 280,750 shares of common stock following the vesting of performance-based Restricted Stock Units (RSUs).
Regulus Therapeutics' Chief Financial Officer, Crispin Calzada, acquired shares of common stock through the vesting of previously granted Restricted Stock Units (RSUs).
Christopher Aker, a Senior VP and General Counsel at Regulus Therapeutics, acquired shares of common stock following the vesting of performance-based restricted stock units.
Preston Klassen, President & Head of R&D at Regulus Therapeutics, acquired 67,500 shares of common stock due to the vesting of performance-based Restricted Stock Units (RSUs).
Director Kathryn J. Collier of Regulus Therapeutics Inc. [RGLS] purchased 4,000 shares of common stock at $1.82 per share on July 25, 2024.
Director William Rastetter acquired 60,000 stock options in Regulus Therapeutics Inc. on May 20, 2024.
Director Stelios Papadopoulos acquired 60,000 stock options in Regulus Therapeutics Inc. on May 20, 2024.
Pascale Witz, a director at Regulus Therapeutics Inc., acquired 60,000 stock options on May 20, 2024, according to a Form 4 filing with the SEC.
Director Hugh Rosen acquired 60,000 stock options in Regulus Therapeutics Inc. on May 20, 2024.
Director Jason Nunn acquired 60,000 stock options in Regulus Therapeutics Inc. on May 20, 2024.
Director Kathryn J. Collier of Regulus Therapeutics Inc. was granted stock options for 60,000 shares on May 20, 2024.
Director Alice Shih-hou Huang acquired 60,000 stock options in Regulus Therapeutics on May 20, 2024.
David Baltimore, a director at Regulus Therapeutics, acquired 60,000 stock options on May 20, 2024, according to a Form 4 filing with the SEC.
Preston Klassen, President & Head of R&D at Regulus Therapeutics Inc., acquired stock options for 528,000 shares at an exercise price of $2.01 on May 20, 2024.
Regulus Therapeutics' CEO, Joseph P. Hagan, was granted 990,000 stock options on May 20, 2024, according to a Form 4 filing with the SEC.
Crispina Balsada, CFO of Regulus Therapeutics, reports acquisition of stock options.
Christopher Ray Aker, Sr. VP & General Counsel of Regulus Therapeutics Inc., acquired stock options for 363,000 shares on May 20, 2024.
Director Kathryn J. Collier acquired 30,000 stock options in Regulus Therapeutics on May 16, 2024, as part of the company's Non-Employee Director's Compensation policy.
Director Jason Nunn acquired 30,000 stock options in Regulus Therapeutics Inc. on May 16, 2024, as part of the company's Non-Employee Director's Compensation policy.
Director David Baltimore acquired 30,000 stock options in Regulus Therapeutics Inc. on May 16, 2024, according to a Form 4 filing.
Director Hugh Rosen acquired 30,000 stock options in Regulus Therapeutics Inc. on May 16, 2024, as part of the company's Non-Employee Director's Compensation policy.
Director Pascale Witz acquired 30,000 stock options in Regulus Therapeutics Inc. on May 16, 2024, according to a Form 4 filing.
Director Stelios Papadopoulos acquired 30,000 stock options in Regulus Therapeutics Inc. on May 16, 2024, according to a Form 4 filing with the SEC.
Director William H. Rastetter acquired 30,000 stock options in Regulus Therapeutics Inc. on May 16, 2024, according to a Form 4 filing.
Director Alice Shih-hou Huang receives 30,000 stock options in Regulus Therapeutics.
Director Stelios Papadopoulos of Regulus Therapeutics Inc. reports acquiring 250,000 shares of common stock at $1.60 per share on March 14, 2024.